Effect of storage time of paraffin sections on the expression of PD-L1 (SP142) in invasive breast cancer

被引：0
|
作者：
Jiankun He
Xinran Wang
Lijing Cai
Zhanli Jia
Chang Liu
Xuemei Sun
Si Wu
Chunyan Ding
Zi Zhang
Yueping Liu
机构：
[1] the Fourth Hospital of Hebei Medical University,Department of Pathology
来源：
Diagnostic Pathology | / 18卷
关键词：
Breast cancer; PD-L1; Immunohistochemistry; Paraffin sections; Storage time;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
    Eva Compérat
    André Oszwald
    Gabriel Wasinger
    Justine Wacquet
    Morgan Rouprêt
    Olivier Cussenot
    World Journal of Urology, 2021, 39 : 4067 - 4071
  • [42] PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
    Yoon Jin Cha
    Dooreh Kim
    Soong June Bae
    Sung Gwe Ahn
    Joon Jeong
    Hye Sun Lee
    Soyoung Jeon
    Tae-Kyung Yoo
    Woo-Chan Park
    Chang Ik Yoon
    Scientific Reports, 11
  • [43] PD-L1 (SP142) testing is concordant between Benchmark Ultra and Bond-III stainers
    Comperat, Eva
    Oszwald, Andre
    Wasinger, Gabriel
    Wacquet, Justine
    Roupret, Morgan
    Cussenot, Olivier
    WORLD JOURNAL OF UROLOGY, 2021, 39 (11) : 4067 - 4071
  • [44] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio, Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    MODERN PATHOLOGY, 2020, 33 (SUPPL 2) : 862 - 862
  • [45] The SP142 PD-L1 IHC assay for atezolizumab (atezo) reflects pre-existing immune status in NSCLC and correlates with PD-L1 mRNA
    Williams, J.
    Kowanetz, M.
    Koeppen, H.
    Boyd, Z.
    Kadel, E. E., III
    Smith, D.
    McCleland, M.
    Zou, W.
    Hegde, P. S.
    ANNALS OF ONCOLOGY, 2016, 27
  • [46] PD-L1 expression evaluated by 22C3 antibody is a better prognostic marker than SP142/SP263 antibodies in breast cancer patients after resection
    Cha, Yoon Jin
    Kim, Dooreh
    Bae, Soong June
    Ahn, Sung Gwe
    Jeong, Joon
    Lee, Hye Sun
    Jeon, Soyoung
    Yoo, Tae-Kyung
    Park, Woo-Chan
    Yoon, Chang Ik
    SCIENTIFIC REPORTS, 2021, 11 (01)
  • [47] PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer
    Monneur, Audrey
    Goncalves, Anthony
    Bertucci, Francois
    BULLETIN DU CANCER, 2018, 105 (03) : 261 - 272
  • [48] PD-L1 testing based on SP142 antibody in metastatic triple-negative breast cancer: summary of an expert round-table discussion
    Peg, Vicente
    Lopez-Garcia, Maria Angeles
    Comerma, Laura
    Peiro, Gloria
    Garcia-Caballero, Tomas
    Lopez, Angel Concha
    Suarez-Gauthier, Ana
    Ruiz, Irune
    Rojo, Federico
    FUTURE ONCOLOGY, 2021, 17 (10) : 1209 - 1218
  • [49] PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Using Sp142, Sp263 and E1L3N
    Brunelli, Matteo
    Calio', Anna
    Munari, Enrico
    Pedron, Serena
    Ciocchetta, Elisa
    Bogina, Giuseppe
    Zamboni, Giuseppe
    Martignoni, Guido
    LABORATORY INVESTIGATION, 2020, 100 (SUPPL 1) : 862 - 862
  • [50] Effect of Paraffin Sections Preservation Time on HER2 Expression in Invasive Breast Cancer
    He, Jiankun
    Liu, Hongbo
    Liu, Yueping
    LABORATORY INVESTIGATION, 2023, 103 (03) : S142 - S143
12345